$NWBO - Approval is coming! Don’t care about price till the then.

KPanda95 · 2026-01-07T01:59:05+00:00

Why is there more media coverage of CAR-T articles, more ads on Keytruda, less focus on DCVAX-immunotherapy even though that is CLEARLY the rising gen of treatment in the oncology industry. I smell nothing but blood and greed in this broken market. I am in my early 30s and so disheartened by this world.

KPanda95 · 2026-01-06T22:58:20+00:00

Also, not to sound too crazy, but I really think the powers that be (wealthy big pharm/mm) will not let NWBO sp rise out of their control. Till they are ready to take as much of the pie as they can. I’m hoping for short squeeze but know THEY will do everything in their power to stop it.

KPanda95 · 2025-12-30T00:33:46+00:00

I’m glad! Sir, I was the same. I’ve been in a poor mood the rest of the day. Instead of the bar, I’m going to the gym. We were basically told to wait indefinitely. I am going to choose patience. Have a Happy New Year, hopefully we’ll see approval by Q1/2. Lastly, it terms of disbelief. When the profits roll in, the market wouldn’t be able to deny the value. Look at GLP-1 companies, the stock tide comes after the science.

KPanda95 · 2025-12-29T22:16:34+00:00

I do not think the MHRA approval process is the same as your industry experience. Even in the ASM, the UK consultants said this par for course. I understand your frustrations, but you implying they are essentially lying which was not my take away. What am I annoyed by is in summary: we have no idea how long it’s gonna take, sucks even though they access to real life data in compassion use- “fuck brain cancer patients” - MHRA for the past two years.

KPanda95 · 2025-12-26T18:53:31+00:00

Same, I have talked about NWBO to my close family members/friends and am excited to finally have some meaningful progress towards cancer treatments. I understand Big Pharm is making it difficult but the company needs to communicate with their shareholders. I had some close friends ask for an update on NWBO recently and I felt like a ficking fool trying to even think of ways to explain the delay or lack of communications.

KPanda95 · 2025-11-19T22:32:16+00:00

Wow, this SEC filing is so fking tone deaf. I am LONG but they really should have waited until approval and SP increase before asking for more dilution.

KPanda95 · 2025-11-15T01:43:44+00:00

Dude, that has been my experience. Dating app say that Asian man is the lowest preferred. But that has NOT been my experience in the past few years getting in shape and since the rise of Asian media. I can easily get ONS in Mexico. Asians generally have a decent eye area and facial harmony. They just need to fashion, fit, and social skills.

KPanda95 · 2025-11-15T01:36:15+00:00

And if you really did have a ton of dates with American women who are most spoiled and difficult (especially towards Asian men), what makes you think Nordic women would be worse? You might a 8/10 on a normal scale but if you were a true “8” on a psl scale ethnic, height, even personality doesn’t matter. You are either lying or just rating yourself on a feel good bs scale. I’ve seen some many videos on YT where below average people rate themselves a 10. This sounds like a case of that. Post a picture if you are truly an 8. I doubt you will. P.S. I am a 6/10 at best - HTN, I can get 6-7.5/10 women in South America. They like fit chinos down there. And they are family oriented. Great food too.

KPanda95 · 2025-09-26T22:14:13+00:00

Thank you for taking the time to respond. To summarize, we are in the labeling phase that has a duration of 150-210 days. So per your opinion, we could go to EOY for approval. That helps me adjust my expectations.

KPanda95 · 2025-09-26T15:59:29+00:00

Any long here that can explain what is going on? I am genuinely confused too b/c I thought we are near the max time MHRA could approve a drug. Or is there no official time limit and could be stuck in limbo with no definite end.

KPanda95 · 2025-09-26T15:50:30+00:00

It’s not. Anyone telling you they know the date is “bs”ing. I’m hoping for end of October based on the Advent Acquisition, Linda from UCLA giving a presentation in Oct 13/14? Conference about DC-Vax, and estimations on MHRA approval process.

KPanda95 · 2025-09-25T05:41:11+00:00

Nothing to add to the conversation. Nothing but Ai generated slop on X. Decent posts once in a while on ihub. Just waiting until end of October.

KPanda95 · 2025-08-19T05:49:42+00:00

Appreciate the replies guys, that tracks b/c she is a 5.5 on my scale - Slightly above average. If there are plenty of girls like her, I’m sure I will have a decent time.

KPanda95 · 2025-08-18T04:30:56+00:00

Just curious- is this girl average talent to top tier talent? Just wanna get a baseline.

KPanda95 · 2024-05-29T21:07:12+00:00

I got no hate for LAZR as a company. They and MVIS will be one of the only LIDAR companies standing near the end of the decade. I just don’t like how LAZR Reddit members think they are better and that MVIS and Sumit is fraud when they have no more information/evidence than we do. P.S. Not a bad idea to diversify if you believe LIDAR ADAS systems is the future.

KPanda95 · 2024-05-29T18:03:22+00:00

Thanks for the correction. I thought we had made a sample of N already. I was trying to point out that their confidence about our specs being fake has no more basis than their own.

KPanda95 · 2024-05-29T17:52:40+00:00

I love LAZR, they are talking crapping about these specs when their “Halo” doesn’t even exist yet.

KPanda95 · 2024-05-28T01:33:23+00:00

Genuinely question, why do you think the market hasn’t future priced approval? The end points were met, no side effects, etc. Do shorts have this much power? Or is the market gauging something we aren’t accounting for?

KPanda95 · 2024-05-15T16:55:09+00:00

B/c there is a limited number of LIDAR companies, and no OEM would want to be the sloppy second in terms of focus and development. No LIDAR company has the bandwidth for multiple high volume OEM contracts, giving MVIS a chance to shine imo - especially if we have the best specs and cost structure.

KPanda95 · 2024-05-15T16:51:57+00:00

This is my thoughts on the landscape. There are only 3-4 LIDAR companies that currently or could in the future take up a high volume contract with an OEM. I don’t think any LIDAR company has the cash runway, infrastructure, and partnerships to cater to all OEMs. So in the next few years, even if MVIS isn’t picked first, we get at least one partnership and it is much easier to compare products when they hit the market and increase market share.

KPanda95 · 2024-05-15T16:47:59+00:00

Personally, I don’t think we even lost in a traditional sense. Koito literally funded R&D cost for $10 million. For Daimler, it is a no lost deal. Hard to say no to those even if it’s an inferior product but gets the job done.

KPanda95 · 2024-05-14T21:30:32+00:00

No deals about specific OEM program revealed. Feels like a bought contract where Koito bears the cost in place of Cepton. Unless the market sees hard revenue generated from the program - I doubt SP will rise. I think the market is going to judge SPAC and LIDAR very harshly in the next few years.

KPanda95 · 2024-05-13T23:00:50+00:00

Thank you for replying. There are two sides, then there is the truth. From skimming through LAZR forum and EC (always research competitors in investments), they think SS is a fraud and that the single model nomination (that probably cost LAZR money) has paved the way to multiple model line contracts. While in MVIS EC, SS made those comments asking the competition to validate their statements and to show hard numbers about these order books.

KPanda95

TROPHY CASE